Eva Ciruelos

4.9k citations

76 papers · 2.5k indexed · 2 hit papers · h-index 15

Cancer Research top 2%
- Breast Cancer Treatment Studies 13
- Cancer Genomics and Diagnostics 6
Oncology top 2%
- Cancer Treatment and Pharmacology 39
- HER2/EGFR in Cancer Research 28
Pulmonary and Respiratory Medicine top 2%
- Advanced Breast Cancer Therapies 58
Genetics top 2%
- Estrogen and related hormone effects 8
- Chronic Lymphocytic Leukemia Research 5
Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer 14

Co-authors: Dejan Juric Hope S. Rugo Mario Campone Sibylle Loibl Fabrice André Pierfranco Conté Hiroji Iwata Kenichi Inoue
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Partner nations: Spain United States France

In The Last Decade

Eva Ciruelos

70 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2021 Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
2019 Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Peers

Countries citing papers authored by Eva Ciruelos

Since Specialization

Citations

This map shows the geographic impact of Eva Ciruelos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Ciruelos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Ciruelos more than expected).

Fields of papers citing papers by Eva Ciruelos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Ciruelos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Ciruelos. The network helps show where Eva Ciruelos may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Eva Ciruelos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eva Ciruelos Line = papers co-authored together Eva Ciruelos links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2– breast cancer Pablo Tolosa,Juan Francisco Caldera Montes,Eva Ciruelos	2025	1
2	Oral SERDs: Transforming the treatment of advanced breast cancer—Insights from EMBER-3 Manuel Alva-Bianchi,Rodrigo Sánchez-Bayona,Eva Ciruelos	2025	0
3	Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer. Eva Ciruelos,Tomás Pascual,Guillermo Villacampa,Sònia Pernas,Rodrigo Sánchez-Bayona,José Ponce,Blanca Cantos Sanchez de Ibarguren,Santiago Escrivá-de-Romaní,Antonia Perelló,Álvaro Montaño,Eduardo Martínez de Dueñas,Ana López González,Mireia Melé,Juan de la Haba-Rodríguez,Javier Cortés,Mafalda Oliveira,Lorea Villanueva,Xavier González,Patricia Villagrasa,Aleix Prat	2024	4
4	Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy Sònia Pernas,Esther Sanfeliu,Guillermo Villacampa,J. Salvador,Antonia Perelló,Xavier González,Begoña Jiménez,Maria J. Merino,Patricia Palacios,Tomás Pascual,Emilio Alba,Lorea Villanueva,Samyukta Chillara,J.M. Ferrero-Cafiero,Patricia Galván,Aleix Prat,Eva Ciruelos	2024	0
5	“Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper” Pierfranco Conté,Eva Ciruelos,Giuseppe Curigliano,Michelino De Laurentiis,Lucia Del Mastro,Alessandra Gennari,Antonio Llombart‐Cussac,Miguel Martìn,Francesca Poggio,Aleix Prat,Fabio Puglisi,Cristina Saura	2024	4
6	Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer Rupert Bartsch,David Cameron,Eva Ciruelos,Carmen Criscitiello,Giuseppe Curigliano,François P. Duhoux,Theodoros Foukakis,Joseph Gligorov,Nadia Harbeck,Nathalie LeVasseur,Alicia Okines,Frédérique Penault‐Llorca,Volkmar Müller	2024	3
7	273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2 Patrick Neven,Neil Stahl,María Vidal,M. Martín Jiménez,Peter A. Kaufman,Nadia Harbeck,Kelly K. Hunt,Sarah Carter,F-C Bidard,PA Fasching,Philippe Aftimos,Duncan Wheatley,Erika Hamilton,Rebecca Aft,Swati Kulkarni,Roohi Ismail‐Khan,Claudia Karacsonyi,Shawn T. Estrem,Umut Özbek,Eva Ciruelos	2023	4
8	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studybreakdown → Hope S. Rugo,Florence Lerebours,Eva Ciruelos,Pamela Drullinsky,Manuel Ruíz‐Borrego,Patrick Neven,Yeon Hee Park,Aleix Prat,Thomas Bachelot,Dejan Juric,Nicholas C. Turner,Nickolas A. Sophos,Juan Pablo Zarate,Christina Arce,Yu-Ming Shen,Stuart Turner,Hemanth Kanakamedala,Wei‐Chun Hsu,Stephen Chia	2021	223
9	130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype Eva Ciruelos,Araceli Arrazola García,Javier Cortés,Sònia Pernas,Estefania De Gárate,Mireia Melé,Alfredo Montaño,Noelia Martínez-Jáñez,Mafalda Oliveira,Juan de la Haba-Rodríguez,Estela Vega,A. Perelló Martorell,B. Bermejo De Las Heras,Blanca Cantos Sánchez de Ibargüen,Eduardo Martínez de Dueñas,Elena Vila Navarro,Tomás Pascual,Xavier González,Patricia Villagrasa,A Prat	2021	2
10	5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i) Olga Martínez‐Sáez,Tomás Pascual,Fara Brasó‐Maristany,Núria Chic,Blanca González‐Farré,Esther Sanfeliu,A. Rodríguez,Eduardo Martínez de Dueñas,Patricia Galván,Francesco Schettini,Benedetta Conte,María Vidal,Bárbara Adamo,Montserrat Muñoz-Mateu,Rosina Moreno,Eva Ciruelos,Iris Faull,Justin I. Odegaard,Aleix Prat	2020	0
11	LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) Fabrice André,Eva Ciruelos,Dejan Juric,Sibylle Loibl,Mario Campone,Ingrid A. Mayer,Gábor Rubovszky,Toshinari Yamashita,Bella Kaufman,Yen‐Shen Lu,Kenichi Inoue,Zsuzsanna Pápai,Masato Takahashi,Farhat Ghaznawi,David Mills,Mathilde Kaper,Michelle C. Miller,Pierfranco Conté,Hiroji Iwata,Hope S. Rugo	2020	16
12	351TiP SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER) Mafalda Oliveira,Patricia Villagrasa,Eva Ciruelos,Joaquín Gavilá,Alexandra Cortegoso,Fernando Henao,Estela Vega,J. Salvador,Vanesa Quiroga,(unknown),Serafín Morales,Pablo Tolosa,Fernando Salvador,Xavier González,Cristina Saura	2020	1
13	352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC) Sara A. Hurvitz,Stephen Chia,Eva Ciruelos,Xin Hu,S-A. Im,Wolfgang Janni,Guy Jérusalem,Mario E. Lacouture,Ruth O’Regan,Hope S. Rugo,Yoon Sim Yap,Farhat Ghaznawi,Yunah Han,Fei Su,Sarat Chandarlapaty	2020	9
14	Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancerbreakdown → Fabrice André,Eva Ciruelos,Gábor Rubovszky,Mario Campone,Sibylle Loibl,Hope S. Rugo,Hiroji Iwata,Pierfranco Conté,Ingrid A. Mayer,Bella Kaufman,Toshinari Yamashita,Yen‐Shen Lu,Kenichi Inoue,Masato Takahashi,Zsuzsanna Pápai,Anne-Sophie Longin,David Mills,Celine Wilke,Samit Hirawat,Dejan Juric	2019	1565
15	Neoadjuvant Chemoradiation for Unfavourable Breast Cancer Patients: A Prospective Cohort Study R. Ciérvide,Á. Montero,Mariola Garcia-Ar,Estela Vega,Mercedes Herrero,Natalia Ramírez,Jessica Skaarup,Cristina Márquez,Manuela Parras,Cristina Pernaut,M. I. Vazquez Lopez,Beatriz Rojas,Lina García‐Cañamaque,Ana Laura Pereira-Suárez,Xin Chen,Rosa Alonso,Pedro Parra Caballero Diego Real de Asa Ramn Costa Fern,ez Leton,Eva Ciruelos,Carmen Rubio	2019	1
16	Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial Fabrice André,Eva Ciruelos,Gábor Rubovszky,Mario Campone,Sibylle Loibl,Hope S. Rugo,Hiroji Iwata,Pierfranco Conté,Ingrid A. Mayer,Bella Kaufman,Toshinari Yamashita,Yen‐Shen Lu,Kenichi Inoue,Masato Takahashi,Zsuzsanna Pápai,A.-S. Longin,David Mills,C. Wilke,Samit Hirawat,Dejan Juric	2018	53
17	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer P. Villagrasa Gonzalez,Aleix Prat,Mafalda Oliveira,Lorena de la Peña,Xavier González,J. Cortés Castán,J. Rios,(unknown),Noelia Martínez-Jáñez,A. Perelló Martorell,Isabel Garau,Eduardo Martínez de Dueñas,Serafín Morales,Mireia Melé,B. Bermejo De Las Heras,Eva Ciruelos	2017	4
18	Estimated Costs of Locoregional and Metastatic Recurrences in Patients with HER2+ Breast Cancer in Spain Joan Albanell,Eva Ciruelos,Juan de la Haba-Rodríguez,Miguel Martín,B Muñoz-Molina,Marina de Salas-Cansado,Rámón Colomer	2016	1
19	A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) Fabrice André,Bella Kaufman,Dejan Juric,Eva Ciruelos,Hiroji Iwata,Ingrid A. Mayer,Pierfranco Conté,Hope S. Rugo,Sibylle Loibl,Gábor Rubovszky,Hans Tesch,Kenichi Inoue,Yen‐Shen Lu,L Ryvo,A.-S. Longin,David Mills,C. Wilke,Caroline Germa,Mario Campone	2016	2
20	BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment. Angelo Di Leo,Eva Ciruelos,Wolfgang Janni,Per Eystein Lønning,Ruth O’Regan,Michael Hubalek,Tibor Csőszi,Thomas Decker,Vivianne C. G. Tjan‐Heijnen,Denis Weber,Mona El-Hashimy,S Goteti,Cristian Massacesi,Thomas Bachelot	2015	5

About Eva Ciruelos

Eva Ciruelos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 76 papers that have together received 2.5k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (58 papers), Cancer Treatment and Pharmacology (39 papers), HER2/EGFR in Cancer Research (28 papers), PI3K/AKT/mTOR signaling in cancer (14 papers), Breast Cancer Treatment Studies (13 papers), Estrogen and related hormone effects (8 papers), Cancer Genomics and Diagnostics (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Cancer Research (936 citations), Oncology (1.5k citations) and Pulmonary and Respiratory Medicine (1.4k citations). Eva Ciruelos has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Dejan Juric, Hope S. Rugo, Mario Campone, Sibylle Loibl, Fabrice André, Pierfranco Conté, Hiroji Iwata, Kenichi Inoue, Gábor Rubovszky and Ingrid A. Mayer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact